Resources from the same session
379MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
Presenter: Peter Schmid
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
380MO - SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial
Presenter: yongmei yin
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 379MO and 380MO
Presenter: Barbara Pistilli
Session: Mini oral session - Breast cancer, metastatic
Resources:
Slides
Webcast
382MO - Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
Presenter: Nancy Lin
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
383MO - Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study
Presenter: Komal Jhaveri
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
384MO - Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)
Presenter: John Robertson
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
385MO - A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors
Presenter: Yiqun Du
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
386MO - Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial
Presenter: Philippe Aftimos
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
387MO - First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer
Presenter: Tomás Pascual
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 385MO, 386MO and 387MO
Presenter: Hervé Bonnefoi
Session: Mini oral session - Breast cancer, metastatic
Resources:
Slides
Webcast